Work Here?
Overview
MMS Holdings is a global contract research organization (CRO) focused on regulatory compliance and data-driven solutions for pharmaceutical and biotech sponsors. It delivers services such as regulatory submissions, clinical trial management, data analytics, and medical writing through a service-based model that relies on established processes and experienced advisors. Its work is contract-based, often long-term, aimed at helping clients meet regulatory requirements, run trials efficiently, and advance therapies under FDA guidance. The company differentiates itself with a science-first approach, a strong track record (97% client satisfaction), and involvement in complex areas like enabling MDMA-assisted therapy research, underscoring a commitment to high-quality, compliant outcomes for sponsors globally.
About MMS
Industries
Data & Analytics
Consulting
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Canton, Ohio
Founded
2006
Get referred to MMS
See people who can refer or advise you
Simplify's Take
What believers are saying
- Datacise reached ACDM finalist status in January 2026, validating MMS's software strategy.
- West Coast expansion before BIO 2026 targets venture-backed biotechs and faster sponsor acquisition.
- I-ACT and pediatric-trials partnerships broaden MMS's therapeutic footprint and referral network.
What critics are saying
- MMS still depends on sponsor-funded biotech budgets; trial delays hit revenue fast in 2026.
- Private-equity ownership under Lindsay Goldberg pushes margin discipline before culture and retention.
- Ascendancy in biometrics invites competition from IQVIA, Parexel, and Medidata on bigger accounts.
What makes MMS unique
- Exploristics acquisition added KerusCloud and deep biostatistics, strengthening MMS's data science edge.
- Ben Dudley became President in May 2026, sharpening global commercial and scientific execution.
- Former FDA leaders Somya Dunn and other advisors deepen MMS's regulatory credibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 20%1 year growth
↑ 20%2 year growth
↑ 20%MMS, a clinical research organization, has acquired Exploristics, a biostatistics and data science company. This acquisition enhances MMS' capabilities in advanced clinical trial design and data science, integrating Exploristics' KerusCloud® platform. The move expands MMS' global presence, particularly in Europe, and aims to optimize drug development strategies, reducing time and costs. Exploristics' CEO, Aiden Flynn, joins MMS as Senior VP, Head of Strategic Statistical Consulting.
On January 29, 2024, Orgenesis Inc. acquired all equity interests in Octomera LLC from MM OS Holdings, L.P., an affiliate of Metalmark Capital.
MMS Holdings Inc. plan to expand and grow in the UK and Europe to build on its teams and deliver value to its clients”
EmVenio Research announced the appointment of Mark Mackenzie, MD, as chief medical officer.
MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors.
MMS is Hiring for 21 Jobs on Simplify!
Find jobs on Simplify and start your career today
About MMS
Industries
Data & Analytics
Consulting
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Canton, Ohio
Founded
2006
MMS is Hiring for 21 Jobs on Simplify!
Find jobs on Simplify and start your career today